Patents Issued in March 28, 2017
  • Patent number: 9603851
    Abstract: The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: March 28, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Rolf Grempler, Michael Mark
  • Patent number: 9603852
    Abstract: Disclosed are methods and compositions for treating pulmonary arterial hypertension and/or obesity using inhibitors of prostaglandin transporter (PGT) activity.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: March 28, 2017
    Assignee: Albert Einstein College of Medicine, Inc.
    Inventors: Victor L. Schuster, Yuling Chi
  • Patent number: 9603853
    Abstract: Modified release formulations of viloxazine and methods of administering the same are disclosed. High-drug load formulations of viloxazine are further disclosed.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: March 28, 2017
    Assignee: Supernus Pharmaceuticals, Inc.
    Inventors: Michael L. Vieira, Austin B. Huang, Padmanabh P. Bhatt
  • Patent number: 9603854
    Abstract: Compounds of formula (I): wherein Ra, Rb, Rc, Rd, R1, R2, R3, R4, R5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: March 28, 2017
    Assignees: LES LABORATOIRES SERVIER, VERNALIS (R&D) LTD
    Inventors: Thierry Le Diguarher, Patrick Casara, Jérôme-Benoît Starck, Jean-Michel Henlin, James Edward Paul Davidson, James Brooke Murray, Christopher John Graham, I-Jen Chen, Olivier Geneste, John Hickman, Stéphane Depil, Arnaud Le Tiran, Miklos Nyerges, Guillaume De Nanteuil
  • Patent number: 9603855
    Abstract: Formulations and methods for growing hone in a site specific location using an osteogenic molecule such as a prostaglandin, and a delivery vehicle which is preferably a polymer matrix.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: March 28, 2017
    Inventors: Sandy Marks, Albert G. Prescott, Paul Odgren
  • Patent number: 9603856
    Abstract: A pharmaceutical composition for use as medicament that inhibits inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person/body-weight.
    Type: Grant
    Filed: November 3, 2014
    Date of Patent: March 28, 2017
    Assignee: FLAMINA HOLDING AG
    Inventor: Michael May
  • Patent number: 9603857
    Abstract: Model and method of treating inflammatory diseases. Traditional treatments for such diseases include administering to the patient toxic anti-inflammatory drugs. Following stabilization of the symptoms, the drug doses are tapered down to minimize side effects, as a result of which inflammation remains high and the disease is rarely cured. A chemistry-based disease model concludes that irrespective of the role that inflammation plays in the disease, inflammation reduction will impede disease initiation and progression. Managing and controlling inflammatory diseases requires reducing inflammation to acceptable normal values. Non-toxic ways such as non-steroidal anti-inflammatory drugs, anti-inflammatory diets, and regular exercise allow such reduction in inflammation to normal values, thereby slowing down or arresting disease progression and allowing the discontinuation or reduction of toxic anti-inflammatory therapy while maintaining low inflammation using non-toxic therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 28, 2017
    Inventor: Kaplesh Kumar
  • Patent number: 9603858
    Abstract: The present invention relates to methods of treating, preventing, or decreasing the occurrence of a condition characterized by Th2 overactivation or impaired Th1, or mitigating symptoms associated with a condition characterized by Th2 overactivation or impaired Th1, comprising orally administering to a subject in need thereof an effective amount of a composition comprising a plant stanol and/or plant stanol ester. The present invention also relates to methods of improving the health status of a subject suffering from asthma and increasing the levels of IL-10 in a subject in need thereof.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: March 28, 2017
    Assignee: RAISIO NUTRITION LTD.
    Inventors: Florence Brull, Ronald P. Mensink, Jogehum Plat
  • Patent number: 9603859
    Abstract: Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting wound healing in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of a tissue wound. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 28, 2017
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Paul B. Savage
  • Patent number: 9603860
    Abstract: A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: March 28, 2017
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Dominique Drouin, Cécile Boyer-Joubert
  • Patent number: 9603861
    Abstract: The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration consisting essentially of a vitamin D metabolite, calcipotriol, and nicotinamide, which are particularly effective in treating and in the maintenance therapy of psoriasis and other related dermal disorders and diseases.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 28, 2017
    Assignee: Dermipsor Ltd.
    Inventors: Avikam Harel, Zeev Even-Chen, Olga Bloch
  • Patent number: 9603862
    Abstract: The invention provides a method of increasing a deacetylase activity of SIRT5 by contacting SIRT5 with an agent that binds SIRT5 and reduces the Km of SIRT5 for a substrate, thereby increasing the deacetylase activity of SIRT5. The invention also provides a method for treating a urea cycle disorder in a mammal, as well as a method of assaying a sirtuin modulator.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: March 28, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Anthony Sauve, Yana Cen
  • Patent number: 9603863
    Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: March 28, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Natalia Dyatkina, Julian Alexander Symons, David Bernard Smith
  • Patent number: 9603864
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: March 28, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Lawrence M. Blatt, Leonid Beigelman, Julian Alexander Symons, David Bernard Smith
  • Patent number: 9603865
    Abstract: It is disclosed a method for treating hepatitis B virus infection or hepatitis B virus/hepatitis delta virus co-infection, the method comprising administering to a subject in need of such treatment a first pharmaceutically acceptable agent that comprises at least one phosphorothioated nucleic acid polymer and a second pharmaceutically acceptable agent that comprises at least one nucleoside/nucleotide analog HBV polymerase inhibitor.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: March 28, 2017
    Assignee: REPLICOR INC.
    Inventor: Andrew Vaillant
  • Patent number: 9603866
    Abstract: An anti-fatigue composition consisting of 20(S)-protopanoxadiol and lycium barbarum polysaccharide. Experiments prove that the composition exhibits a significant anti-fatigue effect. In comparison with the effect attained by the single use of lycium barbarum polysaccharide or 20(S)-protopanoxadiol, the combined use of 20(S)-protopanoxadiol and lycium barbarum polysaccharide exerts an obvious synergistic effect.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 28, 2017
    Assignee: Shang Hai Innovative Research Center of Traditional Chinese Medicine
    Inventors: Changjiang Xu, Weiguo Jia, Chunying Yu, Wenjing Zhang, Qiyuan Han, Qiang Ge, Qinlin Wang, Zirong Yang
  • Patent number: 9603867
    Abstract: A pharmaceutical composition for improving wound healing is provided. The pharmaceutical composition includes (a) hyaluronic acid or its derivation, (b) an effective amount of an active ingredient; and optionally (c) pharmaceutically acceptable carriers and/or excipients. In one embodiment, the active ingredient includes vitamin. In another embodiment, the active ingredient includes acexamic acid. In still another embodiment, the pharmaceutical composition can further comprise sorbic acid.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: March 28, 2017
    Assignee: YUNG SHIN PHARM. IND. CO., LTD.
    Inventors: Chiung-Ju Tsai, Yen-Ling Yi, Man-Hsin Wang, Shih-Lung Chang, Chia-Chun Lee
  • Patent number: 9603868
    Abstract: The present invention is directed to a substantially homogeneous miscible liquid adhesive composition comprising a relatively high number average molecular weight (Mn=6,000-10,000 g/mole) multi-arm star polymer having polyisobutylene chains terminated with cyanoacrylate groups (High-Ø(PIB-CA)3); 2-octyl cyanoacrylate (Oct-CA); and a low boiling point biocompatible solvent having a boiling point of not more than 37° C. When this adhesive composition contacted with living tissue and reacted with a nucleophile, such as water or an initiator, the biocompatible solvent will evaporate and the High-Ø(PIB-CA)3 and Oct-CA will co-polymerize in-situ to form a poly(2-octyl cyanoacrylate)-polyisobutylene co-network suitable for any of a number of biomedical applications, from wound closure and healing of skin tissue, to sealant for surgical cuts.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 28, 2017
    Assignee: The University of Akron
    Inventors: Joseph Kennedy, Istvan Szanka, Amalia Szanka
  • Patent number: 9603869
    Abstract: The invention concerns methods and compositions for treating a neuropsychiatric disorder, wherein the method comprises administering an effective amount of a co-crystal of lithium to a subject in need thereof, wherein the co-crystal comprises lithium, or a pharmaceutically acceptable salt thereof, and an amino acid.
    Type: Grant
    Filed: May 21, 2016
    Date of Patent: March 28, 2017
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Jun Tan, Adam John Smith, Roland Douglas Shytle
  • Patent number: 9603870
    Abstract: The present invention relates to novel gold nanocrystals and nanocrystal shape distributions that have surfaces that are substantially free from organic impurities or films. Specifically, the surfaces are “clean” relative to the surfaces of gold nanoparticles made using chemical reduction processes that require organic reductants and/or surfactants to grow gold nanoparticles from gold ions in solution. The invention includes novel electrochemical manufacturing apparatuses and techniques for making the gold-based nanocrystals.
    Type: Grant
    Filed: July 8, 2010
    Date of Patent: March 28, 2017
    Inventors: Mark Gordon Mortenson, D. Kyle Pierce, David A. Bryce, Adam R. Dorfman, Reed N. Wilcox, Anthony Lockett, Mikhail Merzliakov
  • Patent number: 9603871
    Abstract: Methods of treating gastro-esophageal reflux disease in a subject are provided. The methods can include administering an effective amount of a formulation to treat the gastroesophageal reflux disease, the formulation having a water soluble tannin combined with hydrogen peroxide in a pharmaceutically acceptable excipient; wherein, the tannin has a molecular weight ranging from about 170 Daltons to about 4000 Daltons; the tannin:peroxide weight ratio ranges from about 1:1000 to about 10:1; and, the composition at least inhibits a gastrointestinal spasm associated with gastroesophageal reflux disease in the subject when compared to a second subject in a control group in which the composition was not administered.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 28, 2017
    Assignee: LIVELEAF, INC.
    Inventors: Alexander L Huang, Gin Wu
  • Patent number: 9603872
    Abstract: The invention features methods, kits, and compositions for mitochondrial replacement in the treatment of disorders arising from mitochondrial dysfunction. The invention also features methods of diagnosing neuropsychiatric (e.g., bipolar disorder) and neurodegenerative disorders based on mitochondrial structural abnormalities.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: March 28, 2017
    Assignee: The McLeon Hospital Corporation
    Inventors: Anne M. Cataldo, Peter A. Paskevich, Bruce M. Cohen
  • Patent number: 9603873
    Abstract: Methods and compositions involving miR-122, miR-15b, miR-21, and miR-155, which are useful for the treatment of various diseases, such as cancers, are described. Further described are methods and compositions useful for increasing, activating, or regulating NK cells and surface antigens.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 28, 2017
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Michael A. Caligiuri, Jianhua Yu, Shun He, Rossana Trott
  • Patent number: 9603874
    Abstract: Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 28, 2017
    Assignees: Takara Bio Inc., Mie University
    Inventors: Hiroshi Shiku, Hiroaki Ikeda, Koichi Iwamura, Junichi Mineno, Ikunoshin Kato
  • Patent number: 9603875
    Abstract: A method of making a consumable product containing purified embryonated Trichuris suis ova (TSO) preferably includes steps of: storing the TSO in an acidic solution; adding a food preservative to the acidic solution to produce a preservative-acid-solution; forming a mixing solution by raising the pH of the preservative-acidic-solution to match the pH of a food substance by titrating the preservative-acidic-solution with an acid neutralizer so that the pH changes at a rate of not more than 1 pH unit per 24 hours, preferably to a pH not higher than 5.0; and producing the consumable product by combining the mixing solution and the food substance while maintaining the temperature of the consumable product between 1 degree Centigrade and 47 degrees Centigrade.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: March 28, 2017
    Assignee: NeuOva, LLC
    Inventors: Stephan D. Glenn, Daniel T. Gregory, Jr., Roy A. Stimits, Frank Detlev Goj
  • Patent number: 9603876
    Abstract: The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile, vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: March 28, 2017
    Assignee: New York University
    Inventors: Martin J. Blaser, Ilseung Cho, Laura M. Cox
  • Patent number: 9603877
    Abstract: The present invention relates to an isolated nucleic acid molecule comprising (a) a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a quorum sensing molecule produced by said pathogenic microorganism, (b) one or more second nucleotide sequence said one or more second nucleotide sequence being under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the quorum sensing molecule produced by said pathogenic microorganism and encoding (i) an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and/or an antibiofilm enzyme wherein the antibiofilm enzyme is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and (c) optionally a third nucleotide sequence encoding a protein that contro
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: March 28, 2017
    Assignee: NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Matthew Wook Chang, In Young Hwang, Mui Hua Tan, Elvin Koh
  • Patent number: 9603878
    Abstract: Probiotic compositions containing non-pathogenic microbial entities, e.g., bacterial or fungal entities, are described herein. The probiotic compositions may optionally contain or be used in conjunction with one or more prebiotics. Uses of the probiotic compositions to treat or prevent transplant disorders, e.g., graft-versus-host disease (GVHD), in a subject are also provided.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 28, 2017
    Assignee: Evelo Biosciences, Inc.
    Inventors: David Berry, Shaila Rahman, Johanne Kaplan, Neal Gordon
  • Patent number: 9603879
    Abstract: Disclosed herein are microbiocidal compositions that include spore-forming strains of Bacillus. The compositions may be utilized to treat or prevent disease in aquatic animals such as farmed fish or crustaceans.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 28, 2017
    Assignee: Auburn University
    Inventors: Jeffery Terhune, Mark Liles, Joseph Kloepper
  • Patent number: 9603880
    Abstract: A composition containing a Lactobacillus pentosus TUA4337L strain (accession number: NITE BP-1479), characterized in that the strain has proliferation ability in the small intestines and/or the large intestine, and preferably the small intestines, after having survived in the intestinal tract. Since the composition of the present invention contains lactic acid bacteria having proliferation ability in the intestinal tract, when ingested in the body, the lactic acid bacteria survive to the intestinal tract and proliferate, whereby the fat absorption can be blocked, and the weight gains can be blocked, so that the composition can be suitably used for the purposes of dieting effects.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: March 28, 2017
    Assignee: SUNTORY HOLDINGS LIMITED
    Inventor: Eiji Fukushima
  • Patent number: 9603881
    Abstract: The present invention relates to bioactive fractions isolated from stress-induced photosynthetic organisms. The present invention also relates to methods of producing stress-induced photosynthetic organisms suitable for isolating altered bioactive fractions. The present invention further relates to bioactive compositions, bioactive topical formulations, and methods of their use.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: March 28, 2017
    Assignee: ISP INVESTMENTS LLC
    Inventors: Michael Koganov, Olga Dueva-Koganov, Paul Recht, Artyom Duev
  • Patent number: 9603882
    Abstract: The disclosure provides a method for modulating Th17 cells, including: administering an Antrodia cinnamomea (also named Antrodia camphorata or Taiwanofungus camphoratus) extract to a subject in need thereof, wherein the Antrodia cinnamomea extract has an effect of modulating Th17 cells. The Antrodia cinnamomea extract may include a fruiting body extract of Antrodia cinnamomea or a mycelium extract of Antrodia cinnamomea.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: March 28, 2017
    Assignee: INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE
    Inventors: I-Horng Pan, Shu-Fang Wen, Ming-Han Li, Hsin-Jan Yao, Hsin-Chieh Wu, I-Huang Lu, Joung-Liang Lan, Der-Yuan Chen, Chi-Chien Lin, Ching Lu
  • Patent number: 9603883
    Abstract: Methods of inhibiting bacterial virulence in a subject are provided. The methods can include administering an effective amount of a formulation to inhibit a bacterial virulence in a subject, the formulation having a water soluble tannin combined with hydrogen peroxide in a pharmaceutically acceptable excipient; wherein, the tannin has a molecular weight ranging from about 170 Daltons to about 4000 Daltons; the tannin:peroxide weight ratio ranges from about 1:1000 to about 10:1; and, the composition inhibits a bacterial virulence in the subject when compared to a second subject in a control group in which the composition was not administered.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: March 28, 2017
    Assignee: LIVELEAF, INC.
    Inventors: Alexander L Huang, Gin Wu
  • Patent number: 9603884
    Abstract: A nutritional supplement composition enhances cognitive function and includes huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola. The composition is formulated for oral administration. The huperzine A, vinpocetine, acetyl-L-carnitine, and rhodiola are in a ratio a:b:c:d: respectively such that a as the huperzine A is between about 0.8 and 1.2, b as vinpocetine is between about 80 and 120, c as rhodiola is about 1,600 and 2,400, and d as the acetyl-L-carnitine is between about 8,000 and 12,000.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: March 28, 2017
    Assignee: KeyView Labs, Inc.
    Inventor: Josh Reynolds
  • Patent number: 9603885
    Abstract: An anti-viral composition comprising terpenes and fatty acids found in the Scophulariaceae family of plants is disclosed. It further comprises other lipophillic constituents and the aglycons of the glycosides occurring in said family of plants. Preferably, the composition is derived by extraction of the roots and rhizomes of mixtures of Picrorhiza kurrooa Royle, Picrorhiza scrophularflora Pennell and Neopicrorhiza scrophula iflora. Solvents and solvent combinations are disclosed. The composition is effective against both DNA and RNA viruses and against fungal, bacterial, parasitic and protozoal infections and diseases and also as a hepatoprotective, anti-hyperlipidemic, anti-diabetic and kidney-protective agent. Anti-bodies and vaccines for the cited diseases can be made by administration of the composition to animal or other subjects.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: March 28, 2017
    Assignee: Munisekhar Medasani
    Inventors: Munisekhar Medasani, Satyasayee Divi
  • Patent number: 9603886
    Abstract: A juice drink for hangover treatment containing juiced ingredients of red onion, cucumber, and a leafy green vegetable, such as romaine lettuce to treat a hangover after consumption of alcohol.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: March 28, 2017
    Inventor: George Jordan Laning
  • Patent number: 9603887
    Abstract: The present invention relates to a pharmaceutical composition comprising non-decarboxylated ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resvertrol, and combinations thereof, wherein the composition exhibits an increased but negated psychoactivity with concurrent enhancement in therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
    Type: Grant
    Filed: January 1, 2014
    Date of Patent: March 28, 2017
    Assignee: Brooks Kelly Research, LLC
    Inventor: Brooks J. Kelly
  • Patent number: 9603888
    Abstract: The invention relates to a composition comprising pea protein hydrolysate for the treatment and/or prevention of infection by gastrointestinal pathogens, in particular Helicobacter pylori and/or a disease associated with infection by said gastrointestinal pathogen in mammals.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: March 28, 2017
    Assignee: N.V. Nutricia
    Inventors: Gilda Elise Georgi, Marco Euler, Marko Mank, Andreas Hensel, Michael Niehues, Monika Klapperich, Bernd Stahl
  • Patent number: 9603889
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: March 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, Liping Zhang, Donna D. Wei
  • Patent number: 9603890
    Abstract: Disclosed are compositions and methods for triggering disease selective macropinocytosis. The compositions can serve as a marker of disease activity and as a trigger of enhanced macropinocytosis in tissues undergoing disease remodeling such as wound healing, cancer, PAH, inflammation, diabetes, Crohn's disease, ulcerative colitis, ankylosing spondylitis, diseases of the endometrium, psoriasis, irritable bowel syndrome, arthritis, fibrotic disorders, interstitial cystitis, autoimmune diseases, asthma, acute lung injury, and adult respiratory distress syndrome. The compositions can also serve as a receptor for disease selective cell penetrating peptides in the cells and extracellular matrix of diseased tissues.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 28, 2017
    Assignee: Vascular Biosciences
    Inventor: David Mann
  • Patent number: 9603891
    Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 28, 2017
    Assignee: Chonnam National University Hospital
    Inventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
  • Patent number: 9603892
    Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 28, 2017
    Assignee: Chonnam National University Hospital
    Inventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
  • Patent number: 9603893
    Abstract: Provided are a peptide compound prepared by additional synthesis in a drug having an effect of inhibiting restenosis, a composition for inhibiting restenosis and promoting re-endothelialization including the peptide compound, and a stent having a surface coated by using the composition, in order to overcome a restenosis problem in the stent.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: March 28, 2017
    Assignee: Chonnam National University Hospital
    Inventors: In-Ho Bae, Dae Sung Park, So Youn Lee, Eun Jae Jang, Kyung Seob Lim, Myung Ho Jeong
  • Patent number: 9603894
    Abstract: The invention provides a solution to the problem of delivering molecules in a physiologically relevant manner to direct cell fate. For example, a Notch ligand molecule is presented in a microenvironment that mimics the environment encountered in vivo. Accordingly, the invention features a cell delivery vehicle comprising a biocompatible hydrogel or polymer and a composition that binds to a Notch receptor and methods of directing cell fate, e.g., stem cell differentiation, using such compositions.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: March 28, 2017
    Assignee: President and Fellows of Harvard College
    Inventors: Lan Cao, Kamal H. Bouhadir, David J. Mooney
  • Patent number: 9603895
    Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: March 28, 2017
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Guoqiang Wang, Jiang Long, Xuri Gao
  • Patent number: 9603896
    Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 28, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Heloise Anne Pereira, Anne Kasus-Jacobi, Gina L. Griffith
  • Patent number: 9603897
    Abstract: The invention provides methods for treating tissue damage associated with impaired blood flow using ApoD, or an active variant thereof, or an agent that increases the expression of ApoD. The invention also encompasses active variants of ApoD for use in the methods.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: March 28, 2017
    Assignee: Massachusetts Institute of Technology
    Inventors: Kosuke Tsukamoto, Monty Krieger
  • Patent number: 9603898
    Abstract: A formulation of a diluted amino acid segment is prepared by mixing an amino acid segment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid segment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: March 28, 2017
    Assignee: Deseret Biologicals, Inc.
    Inventors: Jacob L. Carter, Edwin Douglas Lephart
  • Patent number: 9603899
    Abstract: Provided is a method of causing a cell to migrate to a scaffold. Also provided is a method of treating a mammal that has a tissue defect. Further provided is a tissue scaffold comprising platelet-derived growth factor (PDGF). Additionally, a method of making a tissue scaffold capable of recruiting a cell is provided.
    Type: Grant
    Filed: October 3, 2011
    Date of Patent: March 28, 2017
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jeremy J. Mao, Wenli Zhao
  • Patent number: 9603900
    Abstract: The present invention relates to the use of pituitary adenylate cyclase activating polypeptide (PACAP) in the treatment of viral diseases and infectious diseases caused by viruses in aquatic organisms. PACAP, alone or combined with an antiviral molecule, demonstrated its effectiveness by increasing the survival of fish or crustaceans infected by viruses when it was administered orally, by injection or by immersion baths. Furthermore, it was observed that treated organisms keep or increase its weight as compared to infected and non-treated organisms. PACAP or PACAP-containing combinations decreased the viral load in tissues and organs susceptible to viral infections as it was determined by RT-PCR.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: March 28, 2017
    Assignee: CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA
    Inventors: Mario Pablo Estrada Garcia, Juana Maria Lugo Gonzalez, Yamila Carpio Gonzalez, Carolina Tafalla Pineiro